We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER: Novo Nordisk’s Wegovy Needs ‘Significant’ Discount to Be Cost-Effective
ICER: Novo Nordisk’s Wegovy Needs ‘Significant’ Discount to Be Cost-Effective
Novo Nordisk’s Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, shows better efficacy for weight loss than its peers but it requires a significant discount to be cost-effective, according to a new analysis from the Institute for Clinical and Economic Review (ICER).